Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.62 |
| ▸ | PPARA | Q07869 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10774024 | 0.98 | PPARG (0.65) | PPARGPPARAATMKDM4ECA2 | |
| SCHEMBL10771261 | 0.98 | PPARG (0.65) | PPARGPPARAATMKDM4ECA2 | |
| SCHEMBL10773021 | 0.98 | PPARG (0.65) | PPARGPPARAATMKDM4ECA2 | |
| SCHEMBL2759507 | 0.94 | ATM (0.63) | PPARGPPARAATMKDM4ECA2 | |
| SCHEMBL30869991 | 0.92 | ATM (0.70) | PPARGPPARAATMKDM4ECA2 | |
| SCHEMBL10343404 | 0.92 | ATM (0.70) | PPARGPPARAATMKDM4ECA2 | |
| SCHEMBL23913120 | 0.90 | ATM (0.68) | PPARGPPARAATMKDM4ECA2 | |
| SCHEMBL31556187 | 0.90 | ATM (0.68) | PPARGPPARAATMKDM4ECA2 | |
| SCHEMBL31556190 | 0.90 | ATM (0.68) | PPARGPPARAATMKDM4ECA2 | |
| SCHEMBL9547930 | 0.87 | CYP19A1 (0.61) | ATMKDM4ECA2POLBCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102718785-A | Method for preparing aromatic ring boric acid | ZHEJIANG CHEMPACIFIC CHEMICAL CO LTD | 2012-10-10 | — | — | CN | claimed |
| JP-3124710-A | — | — | None | — | — | JP | disclosed |
| US-20200308195-A1 | DIAZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-01 | — | — | US | disclosed |
| WO-2020118478-A1 | POLYCARBONATE COMPOSITIONS | COVESTRO DEUTSCHLAND AG (DE) | 2020-06-18 | — | — | WO | disclosed |
| US-20190023694-A1 | BROAD SPECTRUM ANTIBACTERIAL ACTIVITY OF NOVEL BISBENZIMIDAZOLES TARGETING TOPOISOMERASE IA AND THE SYNERGISTIC COMPOSITION OF BISBENZIMIDAZOLE WITH EFFLUX PUMP INHIBITORS AGAINST PATHOGENIC BACTERIA | TANDON, VIBHA (IN) | 2019-01-24 | — | — | US | disclosed |
| EP-3099685-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2016-12-07 | — | — | EP | disclosed |
| WO-2015113990-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-08-06 | — | — | WO | disclosed |
| CN-103058828-A | Synthetic method of 3,5-dyhydroxy alkylbenzene protected through alkyl group | UNIV ZHEJIANG TECHNOLOGY | 2013-04-24 | — | — | CN | disclosed |
| US-20130040937-A1 | INHIBITORS FOR TREATING AND PREVENTING HEART FAILURE IN FELINES | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| CN-102718785-A | Method for preparing aromatic ring boric acid | ZHEJIANG CHEMPACIFIC CHEMICAL CO LTD | 2012-10-10 | — | — | CN | disclosed |
| CN-1925854-A | Thiazoles and oxazoles useful as modulators of ATP-binding cassette transporters | VERTEX PHARMA (US) | 2007-03-07 | — | — | CN | disclosed |
| US-20060234053-A1 | MICROCAPSULE, METHOD OF MANUFACTURING MICROCAPSULE, ELECTROPHORETIC DEVICE, AND ELECTRIC APPARATUS | SEIKO EPSON CORPORATION (JP) | 2006-10-19 | — | — | US | disclosed |
| EP-1012376-A2 | OXIDATION AND BLEACHING SYSTEM WITH ENZYMATICALLY PRODUCED OXIDIZING AGENTS | Blume, Hildegard (DE) | 2000-06-28 | — | — | EP | disclosed |
| WO-1998059108-A2 | OXIDATION AND BLEACHING SYSTEM WITH ENZYMATICALLY PRODUCED OXIDIZING AGENTS | BLUME, HILDEGARD (DE) | 1998-12-30 | — | — | WO | disclosed |
| US-5214034-A | Improved secretion of nerve growth factor | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1993-05-25 | — | — | US | disclosed |
| US-5102906-A | Alzheimer*s disease | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1992-04-07 | — | — | US | disclosed |
| EP-0261977-B1 | CATECHOL DERIVATIVES, AND PREVENTIVE AND REMEDIAL PREPARATIONS FOR REGRESSIVE DISORDERS IN THE CENTRAL NERVOUS SYSTEM | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-03-04 | — | — | EP | disclosed |
| JP-H03124710-A | PRODUCTION OF POLYETHYLENE COPOLYMER | IDEMITSU PETROCHEM CO LTD | 1991-05-28 | — | — | JP | disclosed |
| US-4985458-A | TREATMENT OF ALZHEIMER*S DISEASE | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1991-01-15 | — | — | US | disclosed |
| EP-0261977-A2 | Catechol derivatives, and preventive and remedial preparations for regressive disorders in the central nervous system | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1988-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308195-A1 | DIAZAINDOLE COMPOUNDS | TLR7, TLR9, TLR1 | PPARG 301/4885PPARA 468/4885ATM 1231/4885 |
| US-20190023694-A1 | BROAD SPECTRUM ANTIBACTERIAL ACTIVITY OF NOVEL BISBENZIMIDAZOLES TARGETING TOPOISOMERASE IA AND THE SYNERGISTIC COMPOSITION OF BISBENZIMIDAZOLE WITH EFFLUX PUMP INHIBITORS AGAINST PATHOGENIC BACTERIA | TOP2B, TOP2A, TOP1 | PPARG 3148/4885PPARA 3929/4885ATM 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.